ASH 2015: First-In-Class Myeloma Highlights
This article was originally published in Scrip
Executive Summary
A number of first-in-class products for acute myeloid leukemia and multiple myeloma provided clinical updates during the American Society for Hematology's (ASH) annual meeting, held Dec. 4-8 in Orlando, Florida.
You may also be interested in...
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights
Agios Pharmaceuticals Inc. will get $200m to kick off a new partnership with longtime collaborator Celgene Corp. under a complex agreement to develop therapies that alter the metabolic state of immune cells to enhance the immune response to cancer.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.